For years, New Zealanders seeking treatment for ADHD have faced long waits, high costs, and limited access to specialists.
Adults often waited months for an assessment, while children cycled through referrals that stretched families thin. That bottleneck is about to shift.
Beginning in February 2026, general practitioners and nurse practitioners will be able to diagnose and prescribe stimulant medications for adults, ending the monopoly psychiatrists and paediatricians have held on initiating treatment.
“Adults often waited months for an assessment, while children cycled through referrals that stretched families thin.”
A structural change to access
The reform marks one of the most significant changes to ADHD care in New Zealand’s recent history.
Until now, only psychiatrists and paediatricians have had the authority to start treatment. GPs and nurse practitioners could prescribe only after a specialist recommendation or once the first script had been written by a specialist.
For patients, this meant navigating queues that could stretch six to twelve months. For clinicians, it meant using their judgement with one hand tied behind their back.
Next February onwards, adults over 18 will be able to receive a diagnosis and initial prescription directly from their GP or nurse practitioner, so long as it falls within their scope of practice. Children and adolescents under 18 will remain under specialist care, with nurse practitioners in paediatric or child and adolescent mental health services also permitted to initiate treatment. Psychiatrists and paediatricians will, of course, retain their authority.
Medicines in scope
The change applies to the three core stimulant medicines used in ADHD treatment: methylphenidate (Ritalin, Rubifen, Concerta, among others), dexamfetamine (Noumed), and lisdexamfetamine (Vyvanse), as confirmed by Medsafe.
These medicines have long been the cornerstone of ADHD management, but their access has been uneven and constrained. Patients frequently reported phoning multiple pharmacies to fill scripts or rationing their doses when shortages hit, according to Pharmac’s consultation outcome.
Why February 2026, not sooner?
The shift was originally meant to take effect in mid-2025. Supply chain realities forced a delay.
Since September 2023, New Zealand has faced intermittent shortages of methylphenidate, particularly in long-acting formulations such as Concerta, Rubifen SR and Ritalin LA, according to Pharmac’s medicine notices.
Global demand has risen sharply, compounded by export restrictions and manufacturing bottlenecks. Officials judged it unwise to widen access during a shortage, lest patients finally able to access treatment be handed empty scripts.
By February, supply chains are expected to stabilise, though reports such as this from the Otago Daily Times suggest shortages remain a risk.
Consultation and consensus
The decision was not rushed. Medsafe and Pharmac, the Ministry of Health’s regulatory and funding arms, jointly oversaw the change. They issued consultation papers in late 2024 and early 2025, receiving around 940 submissions from patients, parents, clinicians, and advocacy groups. Nearly 70 per cent of respondents backed the reform, according to Pharmac.
The Parliamentary hui on ADHD in May 2024, convened by ADHD New Zealand and Green MP Chlöe Swarbrick, had already laid the groundwork. MPs from across the aisle, senior officials, and advocates gathered to confront what had been dubbed a “broken system.”
Around the same time, Julie Legg’s book The Missing Piece provided a searing account of the barriers adults faced. Her story – of seeking diagnosis at age 52 – resonated with many, becoming both an advocacy tool and a public touchstone.
Ministerial endorsement
The reform has had political backing across government. Mental Health Minister Matt Doocey framed it simply: “This is a common-sense change that will make a meaningful difference in many lives of New Zealanders. I have heard stories of many people with ADHD who have been unable to get a diagnosis and treatment in a timely manner because of long wait times and costs associated with seeing a specialist” (1News).
For regulators, the decision illustrates how health licensing and prescribing frameworks evolve under pressure. Medsafe modified approval notices to expand prescriber categories, while Pharmac removed restrictions on who could trigger funded access. Each agency acted within its remit, but the outcome was a coordinated shift in practice.
Implementation architecture
Opening the gate is one thing. Ensuring safe, consistent practice is another.
Health NZ | Te Whatu Ora, along with professional colleges, is preparing training and guidance for new prescribers. The Ministry of Health’s February 2025 briefing outlines a clinical principles framework, professional resources, and consumer education to underpin the change. The Royal New Zealand College of General Practitioners and Nurse Practitioners NZ are developing resources to support assessment and diagnosis.
The reform does not mean every GP clinic will immediately begin diagnosing and prescribing ADHD medications.
Training takes time, and many clinicians are cautious about expanding into what they see as a specialised field. A gradual uptake is expected, with early adopters leading and others following once frameworks and peer norms are established. For patients, that means local access may vary in the early months of the change.
A history of incremental reforms
The February milestone builds on smaller, earlier steps.
In December 2024, the requirement for two-yearly psychiatrist reassessments was removed. On the same date, Pharmac added lisdexamfetamine (Vyvanse) to the funded medicines list, providing an alternative when methylphenidate or dexamfetamine did not work well.
Each of these changes chipped away at bottlenecks, preparing the ground for the broader shift.
The supply shadow
Even once prescribing restrictions are lifted, supply will remain a background concern.
Patients have been forced in recent years to skip doses, swap between formulations, or even go without. The Conversation has reported on patients rationing pills, switching drugs, and chasing pharmacies for stock. Pharmacies have been stretched, fielding desperate calls.
For regulators, the lesson is clear: adjusting prescribing rules without a reliable medicine pipeline risks trading one barrier for another. Ensuring robust procurement and contingency planning is now part of the regulatory equation.
Why it matters for regulators
More than a health policy footnote, this reform is a case study in how regulatory systems respond to advocacy, supply pressures, and clinical realities.
For licensing authorities, it is about recalibrating who can safely prescribe controlled medicines. For funding agencies, it is about aligning authority with access. And for professional colleges, it is about preparing practitioners for new responsibilities.
The ADHD case also demonstrates how consultation can reshape regulatory positions. Nearly a thousand submissions, most in favour, gave regulators political cover and professional insight. Advocacy campaigns and parliamentary hui raised the profile of an issue long seen as niche. In the end, regulators had to adapt.
“For many adults, the ability to walk into a GP clinic rather than navigate psychiatric queues could be life-changing.”
Patients themselves will measure the dividends in shorter waits, lower costs, and earlier treatment. For many adults, especially, the ability to walk into a GP clinic rather than navigate psychiatric queues could be life-changing.
Access to medication is not a cure-all, but timely diagnosis and treatment can reduce risks of depression, anxiety, unemployment, and strained relationships.
Looking ahead
As February approaches, attention will shift from the principle to the practice.
Training, clinical frameworks, and communication campaigns will shape how smoothly the reform beds in. Regulators will watch prescribing patterns, monitor safety data, and track whether inequities in access narrow.
The test will be whether patients across the country – urban and rural, wealthy and low-income – actually feel the difference. If the new regime reduces bottlenecks without introducing new risks, it will stand as a model for other therapeutic areas where specialist bottlenecks choke access.
For years, ADHD care in New Zealand has been marked by scarcity: of specialists, of timely assessments, of medicine supplies. The February 2026 reform does not solve every problem, but it changes the fundamentals. By widening the gate to GPs and nurse practitioners, regulators are reshaping how thousands of New Zealanders will experience care.
For regulators, it is a lesson in balancing safety with access, professional boundaries with public demand, and consultation with decisive action.
